This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.
Mismatch Repair Deficient (dMMR) and Microsatellite Instability-High (MSI-H) Tumors
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center
The use of immune checkpoint inhibitors is emerging as an effective strategy to treat patients with mismatch repair–deficient and microsatellite instability–high tumors. This presentation summarizes data on currently available immunotherapeutic agents for these tumors and details the appropriate management of immune-related hypothyroidism.
These activities, certified for CME/CE/CPE credit, are jointly provided by
in collaboration with